Rituximab (Rituxan) has long been the standard of care for many lymphoma patients with relapsed follicular lymphoma (FL) and marginal zone lymphoma (MZL). Researchers on the AUGMENT trial, a large-scale, multicenter study, sought to improve outcomes for this group of…
The Lymphoma Research Foundation is proud to announce a new partnership with Leukemia & Lymphoma, an international peer-reviewed journal with worldwide print and electronic distribution that publishes articles around key findings in clinical, translational and scientific research relating to hematological…
Miami Beach Philanthropic Community Supports LRF’s Mission to Eradicate Lymphoma and Serve Those Impacted by this Blood Cancer Miami, Fla. (March 28, 2019) – The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma…
Investment Supports Young Investigators Dedicated to Developing Patient Therapies and Lymphoma Cures New York, NY (March 20, 2019) – The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted to funding innovative lymphoma research and serving the lymphoma…
Every year the National Institutes of Health (NIH) and National Cancer Institute (NCI) are required to prepare for the President and the Congress its best professional judgment on the optimal funding needed to make the most rapid progress in the…
At the 2018 ASH Annual Meeting, Catherine Diefenbach, MD (New York University) – a past recipient of LRF’s Clinical Investigator Career Development Award – presented data from cooperative group ECOG-ACRIN’s clinical trial of a new combination of existing therapies ipilimumab…
In the face of declining federal and institutional resources, the Lymphoma Research Foundation’s (LRF) commitment to supporting early career lymphoma researchers has become more critical than ever before. To explore this important topic, the Foundation convened a Biden Cancer Community…
